Engineering glypican-3–directed CAR-NK cell therapies for hepatocellular carcinoma

Treatment of hepatocellular carcinoma (HCC) using adoptive cell therapy is still challenging because of the heterogeneity of antigens expressed on tumor cells and highly suppressive liver microenvironment. Glypican-3 (GPC3) has been identified as one of the most promising therapeutic targets as it is highly expressed in HCC cells but has low expression in normal adult liver tissue. Over the past few years, natural killer (NK) cells have emerged as a promising platform for chimeric antigen receptor (CAR) engineering. Compared with CAR-T cells, CAR-NK cells can be used in allogeneic settings and are generally associated with lower inflammatory toxicity. Advanced CAR technologies, including improved antigen-binding domains and NK-specific signaling domains such as DAP10, DAP12, and 2B4, have enhanced NK-cell activation and cytotoxic activity. Cytokine support systems like IL-15 and IL-21, along with synthetic biology approaches such as hypoxia-responsive systems and logic-gated receptors, are being explored to improve the performance of CAR-NK cells. However, challenges such as immunosuppressive signaling, metabolic stress, and limited immune-cell infiltration in the hepatic tumor microenvironment still need to be addressed. This review discusses recent advances in the development of GPC3-targeted CAR-NK therapies and highlights strategies that may improve their therapeutic potential in HCC.

Authors

Institutions

Publication Details

Journal
Journal of King Saud University - Science
Published
2026-11-14
DOI
https://doi.org/10.25259/jksus_600_2026
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Engineering glypican-3–directed CAR-NK cell therapies for hepatocellular carcinoma

Mohammad Azhar Kamal, Atahar Husein, Azfar Jamal, Asma Naseem et al.
Journal of King Saud University - Science
CAR-T cell therapy research
article

Engineering glypican-3–directed CAR-NK cell therapies for hepatocellular carcinoma

Mohammad Azhar Kamal, Atahar Husein, Azfar Jamal, Asma Naseem, Mohiuddin Khan Warsi, Syed Arif Hussain, Shaista Parveen, Haroonrashid M. Hattiwale
article en

Abstract

Treatment of hepatocellular carcinoma (HCC) using adoptive cell therapy is still challenging because of the heterogeneity of antigens expressed on tumor cells and highly suppressive liver microenvironment. Glypican-3 (GPC3) has been identified as one of the most promising therapeutic targets as it is highly expressed in HCC cells but has low expression in normal adult liver tissue. Over the past few years, natural killer (NK) cells have emerged as a promising platform for chimeric antigen receptor (CAR) engineering. Compared with CAR-T cells, CAR-NK cells can be used in allogeneic settings and are generally associated with lower inflammatory toxicity. Advanced CAR technologies, including improved antigen-binding domains and NK-specific signaling domains such as DAP10, DAP12, and 2B4, have enhanced NK-cell activation and cytotoxic activity. Cytokine support systems like IL-15 and IL-21, along with synthetic biology approaches such as hypoxia-responsive systems and logic-gated receptors, are being explored to improve the performance of CAR-NK cells. However, challenges such as immunosuppressive signaling, metabolic stress, and limited immune-cell infiltration in the hepatic tumor microenvironment still need to be addressed. This review discusses recent advances in the development of GPC3-targeted CAR-NK therapies and highlights strategies that may improve their therapeutic potential in HCC.

Journal of King Saud University - ScienceVol. 0
Alfaisal University (SA), Prince Sattam Bin Abdulaziz University (SA), Majmaah University (SA), University of Jeddah (SA), International Centre for Genetic Engineering and Biotechnology (IN), University College London (GB), Jamia Millia Islamia (IN)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon